Introduction
Trigeminal neuralgia (TN) is one of the most severe pains known and was first described by John Fothergill in 1773. 1 The most common etiology of trigeminal neuralgia is microvascular compression of trigeminal nerve in its course in posterior fossa. Various tumors have been known to cause trigeminal neuralgia by compression of nerve which includes schwanoma, lipoma, epidermoid, meningioma, chordoma, granuloma, metastasis, and glioblastoma.
2-5 Among all the tumors, compression of trigeminal nerve or its one or more divisions in cavernous sinus by pituitary adenoma is a rare entity. On literature search in PubMed and Medline, we could find only one case of pituitary adenoma compressing V1, V2 in cavernous sinus and leading to trigeminal neuralgia.
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Case Report
A middle-aged person presented with episodic paroxysmal attacks of sharp pain in left V1, V2 divisions and was administered carbamazepine which was gradually increased over a period of few weeks to 1,200 mg per day. He complained of similar type of pain, and an MRI of brain was done which revealed a pituitary macroadenoma involving left cavernous sinus (see ►Fig. 1). Visual acuity was 6/9 and 6/36 for right and left sides, respectively. This diminution of vision was gradual and not sudden. Hormonal workup revealed the tumor as nonfunctional. He was operated by transnasal trans-sphenoidal route. Tumor was soft, grayish with some fluid-filled cystic regions. The cavernous sinus was not disturbed as tumor was soft and could be removed easily from lateral sides. In postoperative period, he was relieved of neuralgia. Histopathological examination confirmed the tumor as pituitary adenoma.
Discussion
The pathophysiology of the headache associated with pituitary tumors is less clear. Dural stretch, invasion of the cavernous sinus, and local compression effects are the possible mechanisms. 7, 8 It has been seen that differences in tumor size were not apparent between those who presented headaches and those who did not. Also, there was no clear relationship between the pituitary volume and headache score. 8, 9 Many patients report headaches after starting pharmacotherapy for adenoma; one explanation given for why headaches get worse after taking dopamine agonist is that the growth of the tumor is transitory or that a neurohormonal mechanism is possible. 10, 11 The degree of extension into the cavernous sinus is not associated with the presence or extent of headache.
Abstract
Compression of trigeminal nerve in cavernous sinus leading to trigeminal neuralgia is one of the rare presentations of pituitary tumor. We report a patient whose presenting complaint was trigeminal neuralgia in V1, V2 distribution and he had pituitary macroadenoma invading ipsilateral cavernous sinus. After surgery, the neuralgia disappeared completely.
Management of trigeminal neuralgia can be either medical or surgical. Carbamazepine is the drug of choice for the treatment of TN. The therapeutic doses range from 600 to 1,200 mg per day. The second option for the management of TN includes phenytoin, baclofen, valproate, and gabapentin. The other options in idiopathic trigeminal neuralgia range from gold standard microvascular decompression to alcohol block of the peripheral branch of trigeminal nerve, percutaneous radiofrequency thermocoagulation of the trigeminal nerve sensory root, and gamma knife.
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However, in patients with tumor, decompression alone seems to be the treatment, and for pituitary adenomas trans-sphenoidal decompression seems to be the best option.
Conclusion
The pituitary adenoma presenting as trigeminal neuralgia is an extremely rare presentation, and the patients can be managed by trans-sphenoidal route only.
